Endometrial cancer is the most common gynecologic cancer in the United States, ranking fourth among all cancers in women in age-adjusted incidence ([@bib1]). The large international variation in incidence rates ([@bib2]) suggests that much of the risk may be modifiable. Factors associated with high estrogen and low progesterone levels, such as estrogen-only hormone replacement therapy and obesity, have been shown to increase the risk of endometrial cancer ([@bib3]). However, the role of other modifiable factors, such as diet and environmental exposures, has not been fully investigated.

Limited data are available regarding the association of vitamin D with endometrial cancer risk. Exposure to ultraviolet B irradiation leads to induction of vitamin D precursor synthesis in the skin and is the main source of vitamin D in humans ([@bib4]). Ecologic studies have described an inverse association between ultraviolet B irradiation and endometrial cancer incidence rates, suggesting a protective role of vitamin D against endometrial cancer ([@bib5], [@bib6]). Diet (mostly through fortification) and supplements are also sources of vitamin D ([@bib4]). A recent review of the only 3 case-control studies that have examined the association between dietary intake of vitamin D and risk of endometrial cancer ([@bib7]--[@bib9]) concluded that the evidence available did not support an association but that it was too limited to draw firm conclusions ([@bib10]).

Conversion of 25-hydroxyvitamin D (25(OH)D) to 1,25-dihydroxyvitamin D (1,25(OH)~2~D), the active vitamin D metabolite, occurs in the endometrium ([@bib11], [@bib12]), although the main site of conversion is the kidney ([@bib4]). In addition, endometrial tissue expresses the vitamin D receptor ([@bib12], [@bib13]), a 1,25(OH)~2~D-activated nuclear transcription factor that regulates the production of proteins involved in cell proliferation and differentiation ([@bib14]). These data support the hypothesis that vitamin D plays a role in the etiology of endometrial cancer. 25(OH)D is considered the best indicator of vitamin D status, because it measures vitamin D resulting from both ultraviolet B exposure and dietary/supplement intake and because it has a longer half-life (2--3 weeks) than 1,25(OH)~2~D (4--6 hours) ([@bib15]--[@bib17]). Because no epidemiologic study to date has examined the hypothesis that circulating 25(OH)D is inversely related to risk of endometrial cancer, a case-control study nested within 6 cohorts in the United States and 1 in Shanghai, China, was conducted to examine this hypothesis as part of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers (VDPP).

MATERIALS AND METHODS
=====================

Study design and population
---------------------------

A detailed description of the overall methods of the VDPP and participating cohorts is provided elsewhere in this issue ([@bib18]). All VDPP cohorts that included women (7 out of 10) participated in the nested case-control study of endometrial cancer: CLUE; the Cancer Prevention Study II Nutrition Cohort (CPS-II); the Multiethnic Cohort Study (MEC); the Nurses' Health Study (NHS); the New York University Women\'s Health Study (NYU-WHS); the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO); and the Shanghai Women\'s Health Study (SWHS) ([Table 1](#tbl1){ref-type="table"}).

###### 

Characteristics of Participants, by Cohort, in the Investigation of Endometrial Cancer Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

  Cohort                                 No. of Cases   No. of Controls   Time From Blood Collection to Cancer Diagnosis, median years (interquartile range)   Circulating 25(OH)D, median nmol/L (interquartile range)   
  -------------------------------------- -------------- ----------------- ------------------------------------------------------------------------------------ ---------------------------------------------------------- -------------------
  CLUE                                   192            192               10.0 (4.8--14.2)                                                                     51.9 (39.4--68.4)                                          56.8 (44.0--71.1)
  CPS-II                                 51             51                2.2 (1.2--3.2)                                                                       60.8 (46.8--77.8)                                          63.5 (46.0--78.9)
  MEC                                    39             39                1.4 (0.6--2.4)                                                                       58.0 (41.5--72.5)                                          61.3 (30.3--77.8)
  NHS[a](#tblfn1){ref-type="table-fn"}   163            325               7.2 (4.2--10.6)                                                                      56.3 (37.2--68.5)                                          52.8 (39.7--69.0)
  NYU-WHS                                139            139               10.7 (5.9--13.1)                                                                     41.9 (28.8--60.0)                                          46.7 (31.1--63.0)
  PLCO                                   147            147               2.6 (0.6--4.7)                                                                       51.3 (39.7--65.2)                                          52.1 (37.1--64.8)
  SWHS                                   99             99                4.7 (2.1--6.6)                                                                       29.9 (22.7--41.6)                                          33.4 (25.3--41.6)
  Total                                  830            992               5.5 (2.3--10.5)                                                                      49.4 (34.6--66.4)                                          50.8 (36.7--67.1)

Abbreviations: CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NHS, Nurses' Health Study; NYU-WHS, New York University Women\'s Health Study; 25(OH)D, 25-hydroxyvitamin D; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SWHS, Shanghai Women\'s Health Study.

A 1:2 case:control ratio was used for the NHS.

Incident cases included *International Classification of Diseases for Oncology* (ICD-O) codes 8010, 8140, 8210, 8260, 8310, 8323, 8380, 8382, 8441, 8460, 8461, 8480, 8481, 8560, and 8570. In situ tumors, as well as Mullerian tumors, stromal tumors, and sarcomas, were excluded. Case ascertainment methods for each cohort are summarized ([@bib18]).

Control selection was done by using incidence density sampling. Individually matched controls were selected from the parent cohort among women who were free of cancer at the date of diagnosis of the case (index date) and who had not had a hysterectomy at the index date (except for the CLUE cohort that did not collect data on hysterectomy). Matching factors included age at blood donation (±1 year, except for CLUE and the Shanghai Women\'s Health Study (±2 years)), date of blood donation (±1 month, except for the NYU-WHS (±3 months)), and race (white, black, Asian, other). All cohorts also matched on menopausal status at blood donation.

Out of the total of 843 cases initially identified, 11 were excluded because of ineligible histology and 2 because the date of diagnosis was before the date of blood donation. Thus, this analysis includes 830 cases and 992 controls (a 1:1 case:control ratio was used, except for the Nurses' Health Study, which used a 1:2 ratio). Histologic confirmation was obtained for 97% of the cases.

Measurement of circulating 25(OH)D
----------------------------------

As reported elsewhere ([@bib18]), all serum or plasma samples were assayed for 25(OH)D at Heartland Assays, Inc. (Ames, Iowa) by a direct, competitive chemiluminescence immunoassay by using the DiaSorin LIAISON 25 OH Vitamin D TOTAL Assay ([@bib19], [@bib20]). Quality control procedures are described ([@bib18]). The inter- and intrabatch coefficients of variation using masked National Institute of Standards and Technology samples were 12.7% and 9.3% for samples at level 1 (∼60 nmol/L) and 13.6% and 11.0% for samples at level 2 (∼35 nmol/L), respectively. Based on the masked quality control samples provided by each cohort, the median interbatch coefficient of variation was 13.2% (range: 4.8%--17.0%), and the median intrabatch coefficient of variation was 9.9% (range: 3.8%--16.4%).

Statistical analysis
--------------------

The statistical analysis was conducted following the general approach and specific methods approved by the VDPP Steering Committee ([@bib18]). Aspects of the analysis specific to the endometrial cancer study are described here. For the main analysis, 25(OH)D concentrations were grouped in a priori defined, clinically relevant, categories (\<25.0, 25.0--\<37.5, 37.5--\<50.0, 50.0--\<75.0, 75.0--\<100.0 and ≥100 nmol/L). The 50--\<75 nmol/L category was used as the referent category. Because of the small number of subjects in the top category (≥100 nmol/L), the two top categories were combined (≥75 nmol/L) for stratified and subgroup analyses. Analyses were also conducted after classifying women into 25(OH)D quartiles using cohort- and season-specific cutpoints, with the lowest quartile as referent category. In these analyses, seasons were defined as winter (December to May) or summer (June to November). Circulating 25(OH)D was also analyzed as a natural log-transformed continuous variable.

The seasonal variations in concentrations of 25(OH)D were taken into account in various ways: 1) by matching on date of blood draw and taking the matching into consideration in the statistical analysis; 2) by conducting analyses on quartiles using season-specific cutpoints; and 3) by conducting analyses using residuals from regression of 25(OH)D on week of the year, in an attempt to take into account the gradual nature of changes in concentrations of 25(OH)D over the year better than by adjusting for season ([@bib18]).

The conditional logistic regression model was used for the main analysis to take into account the matched design. Because a comparison of conditional and unconditional logistic regression models using the full dataset showed that the odds ratios obtained by the two methods were nearly identical, stratified and subgroup analyses were conducted using the unconditional logistic regression model and adjusting for the matching factors (cohort, race, age (log-transformed) and season at blood draw). The use of unconditional logistic regression prevented loss of data in analyses stratifying by factors not used in the matching.

Data on potential confounders were collected from each cohort and standardized as described in ([@bib18]). For most variables, data collected at, or close to, blood donation were used. For oral contraceptive and hormone replacement therapy use, data up to the index date were used for the Nurses' Health Study and the NYU-WHS, whereas data collected at, or close to, blood donation were used for the other cohorts. Both conditional and unconditional logistic regression models based on the full dataset are presented adjusting for the following known endometrial cancer risk factors: education, menopausal status, age at menarche, parity, oral contraceptive use, hormone replacement therapy use, body mass index, smoking, history of high blood pressure, and history of diabetes. To assess which factors contributed to confounding, the change in the 25(OH)D regression coefficient in the conditional logistic regression model upon addition of each risk factor, one at a time, was examined. Because only body mass index changed the 25(OH)D coefficient by more than 10%, stratified/subgroup analyses are presented adjusting for this factor only. Analyses adjusting for body mass index on the continuous, log-transformed, scale led to odds ratios qualitatively similar to those of the analysis adjusting for body mass index as a categorical variable (\<25, 25--\<30, ≥30 kg/m^2^, missing), but resulted in a smaller sample size since subjects missing body mass index data were excluded from these analyses. Therefore, results are presented adjusting for body mass index as a categorical variable.

Analyses stratifying by known endometrial cancer risk factors were also conducted and possible effect modification of the 25(OH)D-endometrial cancer association by these factors was assessed by conducting interaction tests ([@bib18]). Because of the known biological interactions between vitamin D and calcium, we were also interested in conducting an analysis stratifying by calcium supplement use; however, because of the small number of calcium supplement users, we were only able to conduct an analysis among non users of calcium supplements. An analysis limited to whites was also conducted. Finally, an analysis excluding cases with ICD-O codes other than 8010, 8140, 8380, 8382 was conducted to assess a possible effect of vitamin D limited to endometrioid tumors.

A meta-analysis assuming a random effects model was conducted to assess between-cohort heterogeneity and to compute overall odds ratios for endometrial cancer associated with the low (\<25 nmol/L) and high (≥75 nmol/L) 25(OH)D categories, as compared to the 50--\<75 nmol/L category ([@bib21]). Cohort-specific odds ratios were computed using the conditional logistic regression model and adjusting for body mass index. Heterogeneity of cohort-specific estimates was measured using the DerSimonian and Laird Q statistic ([@bib22]) and data are presented as forest plots. Finally, to explore the influence of each cohort on our results, the main analysis (using conditional logistic regression and adjusting for all risk factors for endometrial cancer listed above) was repeated excluding one cohort at a time.

RESULTS
=======

[Table 1](#tbl1){ref-type="table"} describes the number of cases and controls from each cohort and the median time between blood donation and diagnosis for the cases, which varied from 1.4 year (Multiethnic Cohort Study) to 10.7 years (NYU-WHS). Among controls, a two-fold variation in median 25(OH)D concentrations was seen across cohorts with the lowest median observed in Shanghai Women\'s Health Study (33.4 nmol/L) and the highest in the Cancer Prevention Study II Nutrition Cohort (63.5 nmol/L).

[Table 2](#tbl2){ref-type="table"} describes characteristics of the cases and controls. The median age at blood donation was 58 years and at diagnosis 64 years. Most subjects were white (79.2% of cases). Compared to controls, cases had younger age at menarche (*P* = 0.02) and older age at menopause (*P* = 0.09). Cases were also more likely than controls to be obese (*P* ≤ 0.0001), to be never smokers (*P* = 0.04) and to have a history of high blood pressure (*P* = 0.0005) or diabetes (*P* = 0.003). Cases were less likely than controls to report oral contraceptive use (*P* = 0.09). Overall, the median concentration of 25(OH)D was slightly lower in cases than in controls (49.4 nmol/L and 50.8 nmol/L, respectively, *P* = 0.08), and the proportions of women with vitamin D concentrations less than 25 nmol/L or 37.5 nmol/L were slightly higher among cases than controls.

###### 

Selected Characteristics of Case Subjects and Control Subjects in the Study of Endometrial Cancer Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

  Characteristic                                                    Cases (*N* = 830)   Controls (*N* = 992)   *P* Value[a](#tblfn2){ref-type="table-fn"}                                       
  ----------------------------------------------------------------- ------------------- ---------------------- -------------------------------------------- ----- ------ ---------------------- -------------------------------------
  Age at blood draw, years                                                                                     58 (50--65)                                               58 (50--64)            Matched
  Age at diagnosis, years                                                                                      64 (58--70)                                                                      
  Race[b](#tblfn3){ref-type="table-fn"}                                                                                                                                                         Matched
      White                                                         657                 79.2                                                                819   82.6                          
      Black                                                         18                  2.2                                                                 23    2.3                           
      Asian                                                         120                 14.5                                                                118   11.9                          
      Other                                                         23                  2.8                                                                 26    2.6                           
  Education[b](#tblfn3){ref-type="table-fn"}                                                                                                                                                    0.22
      Less than high school                                         152                 18.3                                                                164   16.5                          
      Completed high school                                         203                 24.5                                                                183   18.4                          
      Vocational school                                             32                  3.9                                                                 45    4.5                           
      Some college                                                  232                 28.0                                                                333   33.6                          
      College graduate                                              102                 12.3                                                                136   13.7                          
      Graduate studies                                              82                  9.9                                                                 122   12.3                          
  Height, cm                                                                                                   162.6 (157.5--167.6)                                      163 (157--168)         0.76
      Missing                                                       73                  8.8                                                                 104   10.5                          
  Weight, kg                                                                                                   70.5 (61.4--83.9)                                         65.8 (59--75)          \<0.0001
      Missing                                                       104                 12.5                                                                108   10.9                          
  Body mass index, kg/m^2^                                                                                                                                                                      \<0.0001
      \<25                                                          255                 30.7                                                                459   46.3                          
      25--\<30                                                      229                 27.6                                                                291   29.3                          
      ≥30                                                           239                 28.8                                                                132   13.3                          
      Missing                                                       107                 12.9                                                                110   11.1                          
  Age at menarche, years                                                                                       12.5 (12--14)                                             13 (12--14)            0.02
      Missing                                                       131                 15.8                                                                138   13.9                          
  History of full-term pregnancy                                                                                                                                                                0.12
      Yes                                                           561                 67.6                                                                722   72.8                          
      No                                                            98                  11.8                                                                94    9.5                           
      Missing                                                       171                 20.6                                                                176   17.7                          
  Ever used an oral contraceptive                                                                                                                                                               0.09
      Yes                                                           254                 30.6                                                                363   36.6                          
      No                                                            465                 56.0                                                                522   52.6                          
      Missing                                                       111                 13.4                                                                107   10.8                          
  Menopausal status[b](#tblfn3){ref-type="table-fn"}                                                                                                                                            Matched
      Premenopause                                                  235                 28.36                                                               273   27.5                          
      Perimenopause                                                 29                  3.5                                                                 36    3.6                           
      Postmenopause                                                 558                 67.2                                                                680   68.5                          
  Age at menopause, years                                                                                      52 (49--53)                                               51 (47--53)            0.09
      Missing                                                       295                 35.5                                                                328   33.1                          
  Ever used HRT                                                                                                                                                                                 --[c](#tblfn4){ref-type="table-fn"}
      Yes                                                           302                 36.4                                                                409   41.2                          
      No                                                            420                 50.6                                                                475   47.9                          
      Missing                                                       108                 13.0                                                                108   10.9                          
  Smoking status[b](#tblfn3){ref-type="table-fn"}                                                                                                                                               0.04
      Never                                                         512                 61.7                                                                543   54.7                          
      Former                                                        232                 28.0                                                                325   32.8                          
      Current                                                       74                  8.9                                                                 116   11.7                          
  Physical activity                                                                                                                                                                             0.69
      Sedentary                                                     228                 27.5                                                                264   26.6                          
      Light                                                         163                 19.6                                                                197   19.9                          
      Moderate                                                      140                 16.9                                                                188   19.0                          
      Vigorous                                                      145                 17.5                                                                196   19.8                          
      Missing                                                       154                 18.6                                                                147   14.8                          
  History of high blood pressure[b](#tblfn3){ref-type="table-fn"}                                                                                                                               0.0005
      Yes                                                           270                 32.5                                                                248   25.0                          
      No                                                            547                 65.9                                                                735   74.1                          
  History of diabetes[b](#tblfn3){ref-type="table-fn"}                                                                                                                                          0.003
      Yes                                                           50                  6.0                                                                 30    3.0                           
      No                                                            760                 91.6                                                                948   95.6                          
  Caloric intake, kcal/day                                                                                     1,613 (1,276--1,993)                                      1,634 (1,286--2,027)   0.52
      Missing                                                       140                 16.9                                                                140   14.1                          
  Vitamin D, IU/day                                                                                            161 (98--237)                                             179 (105--305)         0.86
      Missing                                                       140                 16.9                                                                140   14.1                          
  Energy-adjusted vitamin D, IU/day                                                                            179 (117--252)                                            197 (126--311)         0.76
      Missing                                                       140                 16.9                                                                140   14.1                          
  Current use of multivitamins[b](#tblfn3){ref-type="table-fn"}                                                                                                                                 0.83
      Yes                                                           243                 29.3                                                                297   29.9                          
      No                                                            547                 65.9                                                                652   65.7                          
  Current use of vitamin D supplements                                                                                                                                                          0.06
      Yes                                                           32                  3.9                                                                 54    5.4                           
      No                                                            297                 35.8                                                                440   44.4                          
      Missing                                                       501                 60.4                                                                498   50.2                          
  Current use of calcium supplement                                                                                                                                                             0.55
      Yes                                                           170                 20.5                                                                223   22.5                          
      No                                                            437                 52.7                                                                514   51.8                          
      Missing                                                       223                 26.9                                                                255   25.7                          
  Season of blood draw                                                                                                                                                                          --[d](#tblfn5){ref-type="table-fn"}
      Winter                                                        134                 16.1                                                                167   16.8                          
      Spring                                                        192                 23.1                                                                236   23.8                          
      Summer                                                        262                 31.6                                                                295   29.7                          
      Fall                                                          242                 29.2                                                                294   29.6                          
  25(OH)D, nmol/L                                                                                              49.4 (34.6--66.4)                                         50.8 (36.7--67.1)      0.08
  25(OH)D, \<25 nmol/L                                              93                  11.1                                                                88    8.9                           0.12
  25(OH)D, \<37.5 nmol/L                                            255                 30.4                                                                263   26.5                          0.07

Abbreviations: HRT, hormone replacement therapy; MEC, Multiethnic Cohort Study; NHS, Nurses' Health Study; 25(OH)D, 25-hydroxyvitamin D; NYU-WHS, New York University Women\'s Health Study; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Wald test from conditional logistic regression, excluding subjects with missing data.

Data were missing for \<5% of subjects.

--, matching factor for CLUE, MEC, NHS, and PLCO.

--, matching on date of blood draw (±1 month except for NYU-WHS, ±3 months).

[Table 3](#tbl3){ref-type="table"} presents results using the conditional logistic regression model. In the crude analysis, there was some suggestion that lower concentrations (\<25 nmol/L) were associated with a small increased risk of endometrial cancer compared with the referent category of 50--\<75 nmol/L (odds ratio = 1.20, 95% confidence interval (CI): 0.83, 1.72) and that higher concentrations (≥100 nmol/L) were associated with a lower risk (odds ratio = 0.78, 95% CI: 0.45, 1.34); however, the test for trend was not statistically significant (*P* = 0.12). After adjusting for body mass index, odds ratios were attenuated, 1.08 (95% CI: 0.73, 1.57) for the \<25 nmol/L 25(OH)D category and 0.90 (95% CI: 0.51, 1.58) for the ≥100 nmol/L 25(OH)D category, and there was no longer any evidence of a trend (*P* = 0.99). As compared to the body mass index-adjusted odds ratios, odds ratios varied only slightly when adjusted for additional known endometrial cancer risk factors. Similarly, analyses using cohort- and season-specific quartiles, residuals, or log-transformed 25(OH)D showed no evidence of association with endometrial cancer risk after adjusting for body mass index (data not shown).

###### 

Odds Ratios and 95% Confidence Intervals for the Association Between Circulating 25(OH)D and Risk of Endometrial Cancer Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers

                                                                   Circulating 25(OH)D, nmol/L                                                                                                                                                                                      
  ---------------------------------------------------------------- ----------------------------- ---- ------ ------------ ----- ----- ------ ------------ ----- ----- ------ ------------ ----- ----- ----- ---------- ---- ----- ------ ------------ ---- ---- ------ ------------ ------
  All                                                              93                            88                       162   170                       163   224                       293   349                    94   126                       25   35                       
      Crude[a](#tblfn6){ref-type="table-fn"}                                                          1.20   0.83, 1.72               1.10   0.83, 1.46               0.86   0.66, 1.11               1.0   Referent              0.88   0.64, 1.20             0.78   0.45, 1.34   0.12
      Body mass index, adjusted[b](#tblfn7){ref-type="table-fn"}                                      1.08   0.73, 1.57               0.97   0.72, 1.30               0.82   0.62, 1.07               1.0   Referent              1.02   0.74, 1.42             0.90   0.51, 1.58   0.99
  Multivariate adjusted[c](#tblfn8){ref-type="table-fn"}                                              1.02   0.68, 1.53               0.91   0.67, 1.24               0.79   0.60, 1.05               1.0   Referent              1.00   0.71, 1.42             0.85   0.47, 1.53   0.81

Abbreviations: CI, confidence interval; HRT, hormone replacement therapy; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.

Conditional logistic regression model, unadjusted.

Conditional logistic regression model, adjusted for body mass index (\<25, 25--\<30, ≥30 kg/m^2^, missing).

Conditional logistic regression model, adjusted for education (less than high school, completed high school, vocational school, some college, college graduate, graduate studies, missing), menopausal status (pre-, peri-, post-, missing), age at menarche (\<13, ≥13 years of age, missing), parity (0, 1, 2, 3, ≥4, missing), oral contraceptive use (never, ever, missing), HRT use (never, ever, missing), smoking (never, former, current, missing), history of high blood pressure (yes, no, missing), history of diabetes (yes, no, missing), and body mass index (\<25, 25--\<30, ≥30 kg/m^2^, missing).

There was no evidence of an association between concentrations of circulating 25(OH)D and endometrial cancer risk in strata defined according to season of blood draw, age at diagnosis, lag-time between blood donation and diagnosis, body mass index, oral contraceptive use or hormone replacement therapy use ([Table 4](#tbl4){ref-type="table"}). There was no evidence of interaction for any of these factors, except hormone replacement therapy (*P* = 0.04). However no consistent trend was observed in either users (*P* = 0.24) or non users of hormone replacement therapy (*P* = 0.36). No associations were observed when analyses were limited to women who did not use calcium supplements, white women, or women with endometrioid tumors.

###### 

Odds Ratios and 95% Confidence Intervals for the Association Between Circulating 25(OH)D and Risk of Endometrial Cancer Within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers With Stratified/Subgroup Analyses[a](#tblfn9){ref-type="table-fn"}

                                                                 Circulating 25(OH)D, nmol/L                                                                                                                                                         
  -------------------------------------------------------------- ----------------------------- ---- ------ ------------ ----- ----- ------ ------------ ----- ----- ------ ------------ ----- ----- ----- ---------- ----- ----- ------ ------------ ------
  All                                                            93                            88                       162   170                       163   224                       293   349                    119   161                       
      Crude[b](#tblfn10){ref-type="table-fn"}                                                       1.22   0.86, 1.75               1.11   0.84, 1.46               0.85   0.66, 1.11               1.0   Referent               0.85   0.64, 1.14   0.11
      Adjusted[c](#tblfn11){ref-type="table-fn"}                                                    1.02   0.70, 1.47               0.93   0.70, 1.24               0.79   0.61, 1.04               1.0   Referent               0.93   0.69, 1.24   0.89
      Adjusted[d](#tblfn12){ref-type="table-fn"}                                                    0.98   0.67, 1.44               0.91   0.67, 1.22               0.80   0.61, 1.05               1.0   Referent               0.93   0.69, 1.26   0.73
  Season[c](#tblfn11){ref-type="table-fn"}                                                                                                                                                                                                           
      December--May                                              54                            55   0.85   0.49, 1.48   77    87    0.82   0.52, 1.31   55    77    0.81   0.50, 1.30   83    107   1.0   Referent   27    49    0.67   0.37, 1.21   0.99
      June--November                                             39                            33   1.16   0.68, 1.98   85    83    1.01   0.69, 1.47   108   147   0.79   0.57, 1.08   210   242   1.0   Referent   92    112   1.02   0.72, 1.44   0.92
  Age at diagnosis, years[c](#tblfn12){ref-type="table-fn"}                                                                                                                                                                                          
      ≤58                                                        31                            27   0.94   0.46, 1.91   43    48    0.70   0.38, 1.28   38    55    0.68   0.39, 1.21   71    71    1.0   Referent   25    43    0.72   0.38, 1.37   0.87
      \>58--64                                                   28                            24   1.38   0.67, 2.84   34    45    0.89   0.49, 1.60   34    50    0.71   0.40, 1.27   63    82    1.0   Referent   32    29    1.50   0.80, 2.81   0.61
      \>64--70                                                   17                            19   0.86   0.38, 1.97   41    43    0.85   0.48, 1.52   46    58    0.90   0.53, 1.51   77    96    1.0   Referent   31    48    0.81   0.45, 1.45   0.91
      \>70                                                       17                            18   0.92   0.41, 2.09   44    34    1.45   0.81, 2.59   45    61    0.86   0.52, 1.42   82    100   1.0   Referent   31    41    0.86   0.48, 1.55   0.45
  Lagtime, years[c](#tblfn12){ref-type="table-fn"}                                                                                                                                                                                                   
      ≤5                                                         44                            42   0.98   0.57, 1.68   72    77    0.82   0.53, 1.26   73    88    0.78   0.52, 1.17   145   151   1.0   Referent   53    78    0.77   0.50, 1.20   0.97
      \>5                                                        49                            46   1.07   0.64, 1.79   90    93    1.04   0.70, 1.54   90    136   0.81   0.57, 1.15   148   198   1.0   Referent   66    83    1.08   0.72, 1.62   0.84
  Body mass index, kg/m^2^[c](#tblfn12){ref-type="table-fn"}                                                                                                                                                                                         
      \<25                                                       24                            47   0.81   0.44, 1.48   31    66    0.76   0.45, 1.29   48    94    0.81   0.52, 1.26   98    162   1.0   Referent   54    90    0.98   0.63, 1.52   0.31
      25--\<30                                                   27                            20   1.42   0.70, 2.86   51    61    0.98   0.59, 1.64   49    66    0.99   0.61, 1.61   76    102   1.0   Referent   26    42    0.85   0.47, 1.53   0.38
      ≥30                                                        38                            15   1.05   0.46, 2.39   63    28    1.13   0.60, 2.12   44    37    0.62   0.34, 1.16   72    38    1.0   Referent   22    14    0.79   0.35, 1.79   0.59
  Oral contraceptive use[c](#tblfn12){ref-type="table-fn"}                                                                                                                                                                                           
      Never                                                      60                            50   1.09   0.67, 1.77   90    101   0.75   0.50, 1.11   96    116   0.84   0.59, 1.21   159   174   1.0   Referent   60    81    0.83   0.55, 1.27   0.96
      Ever                                                       27                            32   0.88   0.45, 1.72   52    55    1.15   0.69, 1.91   44    81    0.75   0.47, 1.22   87    131   1.0   Referent   44    64    1.10   0.67, 1.80   0.71
  HRT use[c](#tblfn12){ref-type="table-fn"}                                                                                                                                                                                                          
      Never                                                      76                            57   1.27   0.78, 2.07   86    98    0.81   0.53, 1.25   93    102   1.10   0.74, 1.64   118   145   1.0   Referent   47    73    0.79   0.49, 1.28   0.36
      Ever                                                       13                            25   0.65   0.31, 1.37   54    59    0.97   0.61, 1.55   48    98    0.55   0.35, 0.84   133   157   1.0   Referent   54    70    0.95   0.61, 1.47   0.24
  No calcium supplements use[c](#tblfn12){ref-type="table-fn"}   41                            35   1.21   0.69, 2.10   76    90    0.85   0.57, 1.26   94    114   0.89   0.62, 1.27   165   192   1.0   Referent   61    83    0.87   0.58, 1.30   0.81
  White race[c](#tblfn12){ref-type="table-fn"}                   46                            53   0.96   0.61, 1.51   116   114   1.09   0.79, 1.50   133   190   0.79   0.60, 1.06   255   317   1.0   Referent   107   145   0.93   0.68, 1.27   0.91
  Endometrioid tumors[c](#tblfn12){ref-type="table-fn"}          93                            88   1.01   0.70, 1.47   162   170   0.93   0.70, 1.24   163   224   0.79   0.61, 1.04   293   349   1.0   Referent   119   161   0.93   0.69, 1.24   0.89

Abbreviations: CI, confidence interval; HRT, hormone replacement therapy; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio.

All *P* values for heterogeneity \> 0.14, except for HRT (*P* = 0.04).

Unconditional logistic regression model, adjusted for matching factors.

Unconditional logistic regression model, adjusted for matching factors and body mass index (\<25, 25--\<30, ≥30 kg/m^2^, missing).

Unconditional logistic regression model, adjusted for education (less than high school, completed high school, vocational school, some college, college graduate, graduate studies, missing), menopausal status (pre-, peri-, postmenopause, missing), age at menarche (\<13, ≥13 years of age, missing), parity (0, 1, 2, 3, ≥4, missing), oral contraceptive use (never, ever, missing), HRT use (never, ever, missing), smoking (never, former, current, missing), history of high blood pressure (yes, no, missing), history of diabetes (yes, no, missing), and body mass index (\<25, 25--\<30, ≥30 kg/m^2^, missing).

No association between circulating 25(OH)D and endometrial cancer risk was observed in the meta-analysis ([Figure 1](#fig1){ref-type="fig"}). The overall, body mass index-adjusted odds ratio comparing the lowest concentration (\<25 nmol/L) to the referent category (50--75 nmol/L) was 1.21 (95% CI: 0.75, 1.98) while the odds ratio associated with concentrations ≥75 nmol/L was 0.98 (95% CI: 0.71, 1.35). There was no evidence of heterogeneity between cohorts (*P* = 0.23 for the comparison of the \<25 nmol/L and 50--75 nmol/L categories and 0.92 for the comparison of the ≥75 nmol/L and 50--75 nmol/L categories). Finally, results from analyses that excluded cohorts one at a time were consistent, showing no statistically significant trend in risk across categories of 25(OH)D concentrations.

![Forest plots for the meta-analysis of the association between circulating 25(OH)D and risk of endometrial cancer within the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Risk estimates, by cohort, are shown for subjects with circulating 25(OH)D concentrations of \<25 nmol/L (A) and ≥75 nmol/L (B) compared with the referent group (50--\<75 nmol/L). Odds ratios and 95% confidence intervals were derived from conditional logistic regression models adjusted for body mass index. The boxes show the odds ratios, the bars show the 95% confidence intervals, and the size of each box is inversely proportional to the variance of the log odds ratio estimate in each cohort. The overall estimates (diamonds) come from a meta-analysis with random-effects modeling. CPS-II and MEC data are not included in the low versus referent category forest plot (A) because of highly unstable risk estimates. CI, confidence interval; CPS-II, Cancer Prevention Study II Nutrition Cohort; MEC, Multiethnic Cohort Study; NHS, Nurses' Health Study; NYU-WHS, New York University Women\'s Health Study; 25(OH)D, 25-hydroxyvitamin D; OR, odds ratio; PLCO, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SWHS, Shanghai Women\'s Health Study.](amjepidkwq114f01_lw){#fig1}

DISCUSSION
==========

Circulating concentrations of 25(OH)D were not associated with risk of endometrial cancer in this nested case-control study based on seven cohorts. Though there was some indication of a trend of decreasing risk with increasing concentrations of 25(OH)D in crude analyses, no trend was observed after adjusting for body mass index. Obesity plays an important role in endometrial cancer etiology because it is associated with increased exposure to estrogen unopposed by progesterone, leading to increased mitotic activity of endometrial cells and greater opportunity for the occurrence of DNA replication errors ([@bib3]). Consistent with results from other studies ([@bib23], [@bib24]), the prevalence of obesity was greater among cases than among controls ([Table 2](#tbl2){ref-type="table"}). Body mass index was also inversely associated with 25(OH)D (cohort-adjusted Spearman correlation coefficient = −0.16 in controls and −0.28 in cases), as was observed in the overall population of controls included in VDPP ([@bib25]); this was expected since vitamin D tends to be sequestered in adipose tissue ([@bib26]). These associations led to negative confounding of the 25(OH)D - endometrial cancer risk relationship by body mass index. Such negative confounding, if ignored, will lead to a spurious association as was observed in our study prior to adjusting for body mass index.

This study is the first to examine the association of endometrial cancer risk with circulating 25(OH)D, which is considered the best marker of vitamin D status ([@bib15]--[@bib17]). The results of this study are in agreement with a review of the literature on vitamin D intake in relation to endometrial cancer which concluded that the limited evidence available regarding vitamin D did not support an association ([@bib10]). These studies, though, did not take into account vitamin D obtained from ultraviolet B exposure. An ecological study of 107 countries reported that endometrial cancer incidence rates were higher at higher latitudes and concluded that low ultraviolet B irradiance, which is associated with lower vitamin D exposure, was associated with endometrial cancer risk ([@bib6]). However, although the authors adjusted for the proportion of the population who were overweight as well as for some other risk factors, the observed association could be due to ecological fallacy since control for body mass index and other risk factors at the individual level was not possible.

A strength of the present study was the availability of individual data, collected prospectively, on known risk factors for endometrial cancer. For most of these risk factors, differences between cases and controls were as expected. Hormone replacement therapy use, though, was less common in cases than in controls. This result appears inconsistent with the known positive association between estrogen-only replacement therapy and endometrial cancer risk. However, our study did not have the ability to assess the association of this variable with disease risk because most participating cohorts matched on use of hormone replacement therapy at entry. In addition, we were not able to distinguish between estrogen-only and estrogen plus progestin formulations, nor to take into account the recency of use, both factors which impact the association of hormone replacement therapy with endometrial cancer risk ([@bib23], [@bib27]--[@bib29]).

Because sun exposure is the main source of vitamin D, circulating concentrations of 25(OH)D are lower in the winter than in the summer months and it is important to take into account such variations to avoid bias ([@bib30]). In addition to matching on date of blood draw, this issue was addressed using various statistical methods. There was no evidence of a protective effect of vitamin D in any of these analyses.

Interactions of vitamin D and vitamin D analogs with estrogens have been reviewed ([@bib31], [@bib32]). Although, to our knowledge, there are no data specific to the endometrium, it has been proposed, based on an animal model of breast cancer, that 1,25(OH)~2~D opposes estrogen-driven proliferation ([@bib33]). In this study, the test for interaction by hormone replacement therapy use was statistically significant (*P* for heterogeneity = 0.04); however, there was no evidence of a protective effect of vitamin D in either ever or never users of hormone replacement therapy ([Table 4](#tbl4){ref-type="table"}). In addition, no association was observed between circulating 25(OH)D and risk of endometrioid endometrial cancer, a subtype strongly associated with estrogen ([@bib34]). Because of the data collection procedures of some of the cohorts and in order to have sufficient numbers of cases, non-endometrioid subtypes (mucinous, serous, clear cell, squamous-cell, mixed) were excluded in this analysis but adenocarcinomas not-otherwise -specified (ICD-O codes 8140 and 8010) (*n* = 462) were combined with endometrioid tumors (*n* = 223). It is therefore likely that some tumors of non-endometrioid subtype were included. However, since endometrioid tumors represent about 80% of all endometrial carcinomas, it is unlikely that an association was missed in this subgroup. Because of small numbers, the association of 25(OH)D with other subtypes of endometrial cancer could not be examined.

The concentrations of circulating 25(OH)D observed in this study were similar to concentrations observed in women in the United States ([@bib35]). Few women, though, had high concentrations and the highest category that could be studied was was ≥100 nmol/L, and for stratified and subgroup analyses, ≥75 nmol/L. Therefore, conclusions cannot be drawn regarding the potential protective effect of higher concentrations of 25(OH)D. However, although a threshold effect is possible, the complete lack of a dose-response relationship in this study argues against a protective role of vitamin D.

Strengths of this study include the prospective assessment of vitamin D status and possible confounders, the inclusion of women living in a wide range of latitudes, a large number of cases and the use of the same laboratory to assay all samples. Only one serum/plasma sample was used for each participant which leads to some measurement error regarding the exposure of interest, i.e. the long-term average circulating level of 25(OH)D. However, circulating concentrations of 25(OH)D appear relatively stable when collected during the same season. A pilot study conducted in the NYU-WHS using the same assay in the same laboratory found an intraclass correlation coefficient of 0.78 (95% CI: 0.64, 0.88) in 30 healthy women who contributed three samples each at yearly intervals (unpublished data). Likewise, in the Nurses' Health Study, the intraclass correlation coefficient for 25(OH)D was 0.72 (95% CI: 0.62, 0.80) in 71 women over a 2--3 year period using a similar assay (unpublished data). These results are comparable to those observed in 144 middle-aged men for whom the Pearson correlation between samples collected 4 years apart was 0.70 ([@bib36]). Such temporal reliability compares favorably to that of other biomarkers that have been found to be associated with disease, such as circulating estrogens (e.g., intraclass correlation coefficient in the 0.50--0.70 range for estradiol over a 2--3 year period ([@bib37], [@bib38])), which have been consistently found to be associated with breast cancer risk ([@bib39]).

In conclusion, after taking into account the effect of body mass index, circulating concentrations of 25(OH)D do not appear to be associated with risk of endometrial cancer.
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